Abstracts Archive - Page 979 of 2425 - ACR Meeting Abstracts

Abstract Number: 370 • 2019 ACR/ARP Annual Meeting
Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Sogol Amjadi¹, Tracy Frech ², Jessica Chan ³, Mary Beth Scholand ⁴, Troy Jaskowski ⁵, Sonia La’ulu ⁵, Jonathan Genzen ⁶, Dorota Lebiedz-Odrobina ⁷ and Ann Tebo ⁶, ¹University of Utah, Department of Internal Medicine, Division of Rheumatology, West Jordan, UT, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³University of Utah, Department of Radiology, salt lake city, UT, ⁴University of Utah, Department of Internal Medicine, Division of Pulmonary Medicine, salt lake city, UT, ⁵ARUP Institute for Clinical and Experimental Pathology, salt lake city, UT, ⁶ARUP Institute for Clinical and Experimental Pathology , University of Utah, Department of Pathology, salt lake city, UT, ⁷University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Fibrotic lung diseases encompass a wide spectrum of clinical entities including connective tissue disease related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune…
Abstract Number: 371 • 2019 ACR/ARP Annual Meeting
Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis
Patil Injean¹, Yvonne Lee ² and Mehrnaz Hojjati ³, ¹Loma Linda University, Loma Linda, ²Loma Linda University Health, Loma Linda, ³Department of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Cardiac sarcoidosis (CS) is a rare, life-threatening disease and the second leading cause of death in patients with sarcoidosis. Currently, the recommended treatment for…
Abstract Number: 372 • 2019 ACR/ARP Annual Meeting
Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience
Gozde Kubra Yardımcı ¹, Alper Sarı ¹, Abdulsamet Erden ², Ertugrul Cagri Bolek ¹, Bayram Farisoğulları ¹, Levent Kilic ³, Berkan Armagan ⁴, Umut Kalyoncu ⁵, Tuncay Hazırolan ⁶, Ali İhsan Ertenli ¹ and Omer Karadag⁷, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey, ⁶Hacettepe University, Division of Radiology, Ankara, ⁷Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that may involve multiple organ systems. IgG4-RD can also lead to large vessel vasculitis and…
Abstract Number: 373 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis
Patrice Cacoub¹, Catherine Chapelon Abric ², Matthieu Resche-Rigon ³, David Saadoun ², Anne Desbois ² and Lucie Biard ³, ¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²GHPS, Paris, France, ³Hôpital Saint Louis, Paris, France
Background/Purpose: To identify prognostic factors and to assess the effects of immunosuppressive drugs on relapse risk in patients presenting with cardiac sarcoidosis (CS).Methods: From a…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 375 • 2019 ACR/ARP Annual Meeting
Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center
Anjani Pillarisetty¹, Mithun Devraj ², Farooq Sheikh ³ and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC, ³MedStar Washington Hospital Center, MedStar Heart and Vascular Institute, Washington, DC
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease of unclear etiology characterized histologically by non-caseating granulomas. While clinically manifest cardiac involvement occurs in only about 5%…
Abstract Number: 376 • 2019 ACR/ARP Annual Meeting
Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study
Okinori Murata¹, Katsuya Suzuki ², Nobuhito Sasaki ³, Tsutomu Takeuchi ² and Makoto Maemondo ³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ³Division of Pulmonary medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
Background/Purpose: Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been…
Abstract Number: 377 • 2019 ACR/ARP Annual Meeting
Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Matthew Baker¹, Khushboo Sheth ¹, Julia Simard ², Stanford Shoor ¹ and Mark Genovese ³, ¹Stanford University, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. When it affects the myocardium, it can result in electrical conduction…
Abstract Number: 378 • 2019 ACR/ARP Annual Meeting
Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years
Lara Sanchez-Bilbao¹, Belén Atienza-Mateo ¹, Iñigo Gonzalez-Mazon ², Jose Luis Martín-Varillas ¹, Rosalia Demetrio ³, Vanesa Calvo-Río ⁴, Eva Peña Sainz-Pardo ⁵, Raul Fernandez-Ramon ³, Jorge Javier Gaitan-Valdizan ³, Miguel A Gonzalez-Gay ¹ and Ricardo Blanco ¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Pediatrics, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Sarcoidosis is a multisystemic inflammatory disease characterized by non-caseating epitheliod granulomas. Ocular involvement is the presenting symptom in approximately 20-30% in form of uveitis,…
Abstract Number: 379 • 2019 ACR/ARP Annual Meeting
Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group
Thieroff George¹, Huzaefah Syed ², Thomas Iden ², Aamer Syed ², Trang Le ² and Alicia Zukas ³, ¹VCU Medical Center, Richmond, VA, ²VCU Medical Center, Richmond, VA, ³Virginia Commonwealth University, Richmond, VA
Background/Purpose: The 2018 Neurosarcoidosis Consortium Consensus Group (NCCG) attempted to increase specificity in diagnosing neurocsarcoidosis from the 2013 World Association of Sarcoidosis and Other Granulomatous…
Abstract Number: 380 • 2019 ACR/ARP Annual Meeting
Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution
Philipp Rustler¹, Dirk Schindler ², Reinhard Voll ¹ and Florian Kollert ³, ¹Division of Rheumatology and Clinical Immunology, Medical Centre - University of Freiburg, Freiburg, Germany, ²Environmental Meteorology, University of Freiburg, Freiburg, Germany, ³Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Sarcoidosis is a multisystemic granulomatous disorder of unknown origin. The central role of macrophages and granuloma formation, the predominant involvement of lung and skin,…
Abstract Number: 381 • 2019 ACR/ARP Annual Meeting
Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis
Christopher Overton¹, Trang Le ¹, Thomas Iden ¹, Aamer Syed ¹, Markos Kashiouris ¹ and Huzaefah Syed ¹, ¹VCU Medical Center, Richmond, VA
Background/Purpose: Hypercalcemia is seen in 2-30% of patients with sarcoidosis and is caused by the overproduction of Vitamin D (VitD) 1,25OH (calcitriol) by macrophages within…
Abstract Number: 382 • 2019 ACR/ARP Annual Meeting
Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis
Keld-Erik Byg¹, Tobias Sejbaek ², Helle Nielsen ³, Zsolt Illes ⁴, Jonna Skov Madsen ⁵, Dorte Olsen ⁶ and Torkell Ellingsen ¹, ¹Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ²Department of Neurology, Odense University Hospital; Department of Clinical Research, University of Southern Denmark, Denmark, Odense, Syddanmark, Denmark, ³Department of Neurology, Odense University Hospital, Department of Clinical Research, University of Southern Denmark, Denmark, Odense, Syddanmark, Denmark, ⁴Department of Neurology, Odense University Hospital, Department of Clinical Research, University of Southern Denmark, Denmark, Odense, Midtjylland, Denmark, ⁵Department of Biochemistry and Immunology, Lillebaelt Hospital, Vejle, Department of Regional Health Research, University of Southern Denmark, Denmark, Vejle, Syddanmark, Denmark, ⁶Department of Biochemistry and Immunology, Lillebaelt Hospital, Vejle, Denmark., Vejle, Syddanmark, Denmark
Background/Purpose: Neurofilament Light Chain (NFL) is an emerging biomarker that is specific for neuronal and axonal damage/degeneration but unspecific regarding the origin of destruction. NFL…
Abstract Number: 383 • 2019 ACR/ARP Annual Meeting
Retroperitoneal Fibrosis- a Single Center Experience
Mert Oztas¹, Emir Cerme ², Izzet Altun ³ and Serdal Ugurlu ⁴, ¹Istanbul University-Cerrahpasa,Department of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Mayo Clinic, Scottsdale, AZ, ⁴Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey
Background/Purpose: Idiopathic retroperitoneal fibrosis (iRPF) is a rare, chronic, progressive disorder of unknown etiology and characterized by the presence of inflammatory and fibrous retroperitoneal tissue…
Abstract Number: 384 • 2019 ACR/ARP Annual Meeting
Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Connie Lam ¹, Stephen Bloom ² and Alberta Hoi³, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, ³School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: The assessment of liver stiffness using liver elastography (Fibroscan) has facilitated early diagnosis of hepatic fibrosis in patients with chronic liver disease, but its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].